New open source project engages universities in neglected diseases drug discovery

[London and New York –  May 3, 2017]
Indian, UK and US students to help discover desperately-needed drug leads for visceral leishmaniasis
The non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) has launched a collaborative project with five universities in India, the UK, and the US to harness the capacity of university teaching laboratories and task students with discovering potential new drugs for patients living with neglected diseases.

Daiichi Sankyo announces collaborative research on drugs for neglected diseases

[Tokyo, Japan – March 30, 2017]
Daiichi Sankyo announces collaborative research on drugs for neglected diseases
Daiichi Sankyo Company, Limited (hereafter, “Daiichi Sankyo”), announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (hereafter, “DNDi”) with regard to a new research program, the Hit-to-Lead Project, with the aim to develop drug treatments for two neglected tropical diseases, leishmaniasis and Chagas disease.

Study confirms key therapeutic advance for children living with HIV and tuberculosis

[Seattle, USA – February 14, 2017]
Landmark study proves that “super-boosting” approach counters negative interaction between key HIV and TB drugs
The non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) has released results of a study in South Africa that will make it easier for healthcare workers to treat children living with HIV who are co-infected with tuberculosis.

African eye worm is worse than it looks: new study shows that the disease leads to increased mortality

[Geneva, Switzerland – October 22, 2016]
Potentially refutes assumption that Loa Loa is a benign disease and highlights R&D gap for filarial diseases
A filarial worm infection called Loiasis that affects over 10 million people in Africa and has been assumed to be a relatively harmless disease could possibly contribute to increased risk of death, according to a study recently published in Lancet Infectious Diseases.

“Towards Ending the Neglect?” DNDi releases update on its Paediatric HIV Programme

[July 2016]
As the International AIDS Conference kicks off in Durban, the Drugs for Neglected Diseases initiative (DNDi) has released an update on its efforts to develop optimal child-adapted antiretroviral formulations. This document details some recent progress towards its final goal of developing “4-in-1” fixed-dose combinations using the World Health Organization (WHO) recommended treat­ment regimen for infants and young chil­dren. DNDi’s update also discusses some promising developments for treatment for children living with both HIV and tuberculosis (TB).

Celgene joins DNDi’s “Drug Discovery Booster” to accelerate discovery of new treatments for neglected diseases

[Summit, New Jersey and Geneva, Switzerland – June 15, 2016]
First US-based biopharmaceutical partner to join global consortium
The biopharmaceutical company Celgene has become the fifth company to join the “Neglected Tropical Diseases Drug Discovery Booster” consortium, a new initiative to accelerate and cut the cost of early stage drug discovery for two of the world’s most neglected diseases, leishmaniasis and Chagas disease.

DNDi, Mundo Sano and Chemo team up to register benznidazole in US and Latin America

[8 June 2016 – Rio de Janeiro, Brazil]
Plans will boost access to Chagas treatment throughout Americas
In a bid to overturn a situation where less than 1% of people with Chagas disease have access to treatment, non-profit drug development organisation Drugs for Neglected Diseases initiative (DNDi), pharmaceutical company Chemo Group and non-profit foundation Mundo Sano are entering into a formal collaboration to boost affordable access to benznidazole, by registering this essential medicine in countries affected by this deadly disease, including the US.
[Español] [Português]

Mycetoma is added to WHO List of ‘Neglected Tropical Diseases’

[28 May 2016 – Geneva, Switzerland]
Move helps bring the disease to the attention of governments and funders
During the 69th World Health Assembly, the decision-making body of the World Health Organization (WHO), the devastating infection mycetoma has been added to WHO’s official list of ‘neglected tropical diseases,’ an important step in addressing the suffering of patients afflicted by this disease around the globe. Mycetoma becomes the 18th disease to be included on this list.

Drugs for Neglected Diseases initiative and Pharco Pharmaceuticals to test affordable hepatitis C regimen with support of Malaysian and Thai governments

[The International Liver Congress 2016, Barcelona, Spain, 13 April 2016]
Potentially pan-genotypic combination of ravidasvir and sofosbuvir to be tested in Malaysia and Thailand with target price of under $300
The Drugs for Neglected Diseases initiative (DNDi) and the Egyptian drug manufacturer Pharco Pharmaceuticals have signed agreements covering the clinical testing and scale-up of a hepatitis C treatment regimen at a price of just under $300.
[Español] [Français] [Português]

Clinical Research Malaysia and the Drugs for Neglected Diseases initiative sign agreement to launch clinical studies for a public health approach to hepatitis C in Malaysia

[Putrajaya, 13 January 2016]
Joint Media Release: Ministry of Health Malaysia and the Drugs for Neglected Diseases initiative (DNDi)
The Drugs for Neglected Diseases initiative (DNDi) and the Ministry of Health of the Government of Malaysia have agreed to work together to develop a public health approach to Hepatitis C within the framework of the future National Strategic Plan on viral hepatitis. The immediate goal is to conduct clinical studies of promising new treatment regimens for Hepatitis C, to be followed by scale-up of treatment for patients, with the overall objective of ensuring equitable access to affordable and effective treatments for patients suffering from this disease in Malaysia.

DNDi statement on KaloBios’ intention to raise price of Chagas drug and file for FDA priority review

[New York, December 14, 2015]
As reported this weekend in the New York Times, the pharmaceutical company KaloBios has announced its intention to register the drug benznidazole with the United States Food and Drug Administration (FDA) and to charge exorbitant prices for this treatment, which is an essential medicine for Chagas disease, the leading parasitic killer in Latin America. By registering this drug in the U.S., KaloBios also hopes to obtain a neglected disease “priority review voucher,” which it would likely be able to sell for a large sum – the latest “priority review voucher” was sold for $350 million.

Although details about this move are still emerging, documents filed with the US Securities and Exchange Commission (SEC) show that KaloBios intends to price benznidazole at levels “similar to Hepatitis C antivirals,” which are some of the most highly-priced drugs on the planet. Currently, benznidazole is available in many Latin American countries for $60-100, while the new generation of Hepatitis C antivirals cost up to $94,000.

World AIDS Day 2015: Study Begins in Kenya for Recently-Approved Paediatric HIV Treatment

[Nairobi, Kenya – 1 December 2015]
One small but important step towards better treatment for children
The Drugs for Neglected Diseases initiative (DNDi) has begun an implementation study of a recently-approved paediatric antiretroviral (ARV) treatment in order to address the urgent need for better medicines for children living with HIV. This study, which has begun in Kenya, is an important step towards DNDi’s ultimate goal of developing, together with the Indian generic pharmaceutical company Cipla Ltd and in partnership with UNITAID, improved and easy-to-take combinations of the key HIV medicines children need to survive into adulthood.

Drugs for Neglected Diseases initiative unveils new plan for neglected patients at a key gathering of experts in India

[New Delhi, 16 October 2015]
Drugs for Neglected Diseases initiative Unveils New Plan for Neglected Patients at a key gathering of experts in India
At a gathering of over 100 global public health experts, notably Dr Soumya Swaminathan, Secretary, Department of Health Research & Director General, Indian Council of Medical Research (ICMR) and Dr A C Dhariwal, Director, National Vector Borne Disease Control Programme of India, as well as scientists, researchers, civil society representatives, and partner organizations, the Drugs for Neglected Diseases initiative (DNDi) unveiled its global Business Plan as well its plans for India and the region to better respond to the needs of patients suffering from neglected diseases. At the occasion, held on 15 October 2015, ICMR and DNDi signed a Memorandum of Understanding to reinforce their research and development (R&D) technical collaboration in the field of neglected diseases and the patronage of the ICMR as a key institutional partner of DNDi.

French Development Agency AFD and DNDi sign partnership agreement for control of leishmaniasis in East Africa

[Paris, France and Geneva, Switzerland – 8 October 2015]
The French Development Agency AFD and the Drugs for Neglected Diseases initiative (DNDi) signed today a partnership agreement EUR for €2 million, spanning to the end of 2018 for the development of a new, safe, and effective oral treatment, to support efforts to control leishmaniasis in East Africa (Sudan, Ethiopia, Kenya and Uganda).
[Français]

DNDi Awarded USD 2.34 Million from New Pooled Fund Mechanism at WHO-TDR in Support of Global Leishmaniasis R&D Demonstration Project

[Geneva, Switzerland – 6 October 2015]
The Drugs for Neglected Diseases initiative (DNDi) has been awarded USD 2.34 million from a new pooled fund for health research and development (R&D) set up by Member States of the World Health Organization (WHO) and hosted by the Special Programme for Research and Training in Tropical Diseases (WHO-TDR), for a large-scale R&D project for the parasitic disease leishmaniasis.
[Español] [Português]